![](https://ml.globenewswire.com/media/b027f538-61a7-4d21-96e2-d4e1a8801d62/small/immunomedics-png.png)
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC) sBLA submission for accelerated approval expected in fourth quarter 2020, pending FDA …